Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Jan Burger, MD
Videos
New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors
11/14/2022
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses...
11/14/2022
Oncology
Sujit Sheth, MD
Videos
Novel Therapies for Non–Transfusion-Dependent and Transfusion-Dependent Thalassemia
11/03/2022
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the...
11/03/2022
Oncology
Norman Latov, MD
Videos
Managing Peripheral Neuropathies Associated With Waldenström Macroglobulinemia
11/02/2022
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the...
11/02/2022
Oncology
Lorenzo Falchi, MD
Videos
Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma
11/02/2022
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents...
11/02/2022
Oncology
Morie Gertz, MD
Videos
Do All Patients Diagnosed With Waldenström Macroglobulinemia Require Immediate Intervention?
11/02/2022
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses...
11/02/2022
Oncology
Paul Richardson, MD
Videos
Novel CELMoD Agents for Multiple Myeloma: Iberdomide and Mezigdomide
10/21/2022
Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Paul Richardson, MD, provides an...
10/21/2022
Oncology
Keith Pratz, MD
Videos
Outpatient Combination Therapy in Patients With Newly Diagnosed AML
10/21/2022
Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Keith Pratz, MD, provides...
10/21/2022
Oncology
Michal Bar-Natan, MD
Videos
Novel Agents for Managing Patients With Relapsed ALL
10/19/2022
Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Michal Bar-Natan, MD, provides...
10/19/2022
Oncology
Elias Jabbour, MD, MD Anderson Cancer Center
Videos
Incorporation of Antibodies Into the Management of Upfront and Relapsed ALL
10/19/2022
Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.
Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.
Elias Jabbour, MD, provides an...
10/19/2022
Oncology
Ehab Atallah, MD
Videos
Management of CML: New Agents and Monitoring for MRD
10/19/2022
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an...
10/19/2022
Oncology

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use